Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

Inclusion Criteria: * Male participants aged ≥18 years. * Histologically confirmed diagnosis of prostate adenocarcinoma. * Classified as low-risk or favorable intermediate-risk prostate cancer according to NCCN criteria: Low-risk: Grade Group 1, PSA \<10 ng/mL, cT1-T2a Favorable intermediate-risk: Grade Group 2, PSA 10-20 ng/mL, cT2b-c Currently managed with active surveillance. * Able and willing to undergo rhPSMA-7.3 (¹⁸F) PET/CT imaging, mpMRI, and confirmatory prostate biopsy. * Able to provide written informed consent. Exclusion Criteria: * A history of other active malignancy within the last 5 years, except for non-melanoma skin cancer. * Contraindication to 3-T mpMRI. * Significant intercurrent morbidity\*\* limiting compliance with study protocols. \*\* Significant intercurrent morbidity refers to a substantial medical condition or complication that arises during a study or treatment, which is severe enough to impact the patient's participation, treatment outcomes, or overall prognosis. These conditions may be unrelated to the primary disease but can influence clinical decision-making, treatment efficacy, and patient safety. Examples include major infections, cardiovascular events, organ failure, or significant worsening of pre-existing comorbidities (https://doi.org/10.1016/S1053-4296(03)00031-6). * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Agent(s) or other agents used in study.